MX2018004553A - Combinación farmacéutica de un antipsicótico atípico y un modulador de nmda para el tratamiento de esquizofrenia, trastorno bipolar, deterioro cognitivo y trastorno depresivo mayor. - Google Patents
Combinación farmacéutica de un antipsicótico atípico y un modulador de nmda para el tratamiento de esquizofrenia, trastorno bipolar, deterioro cognitivo y trastorno depresivo mayor.Info
- Publication number
- MX2018004553A MX2018004553A MX2018004553A MX2018004553A MX2018004553A MX 2018004553 A MX2018004553 A MX 2018004553A MX 2018004553 A MX2018004553 A MX 2018004553A MX 2018004553 A MX2018004553 A MX 2018004553A MX 2018004553 A MX2018004553 A MX 2018004553A
- Authority
- MX
- Mexico
- Prior art keywords
- disorder
- cognitive impairment
- schizophrenia
- treatment
- atypical antipsychotic
- Prior art date
Links
- 239000003693 atypical antipsychotic agent Substances 0.000 title abstract 3
- 229940127236 atypical antipsychotics Drugs 0.000 title abstract 3
- 208000020925 Bipolar disease Diseases 0.000 title abstract 2
- 208000028698 Cognitive impairment Diseases 0.000 title abstract 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 title abstract 2
- 208000010877 cognitive disease Diseases 0.000 title abstract 2
- 201000000980 schizophrenia Diseases 0.000 title abstract 2
- 208000024714 major depressive disease Diseases 0.000 title 1
- 108010024875 GLYX-13 peptide Proteins 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- GIBQQARAXHVEGD-BSOLPCOYSA-N rapastinel Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)N[C@@H]([C@@H](C)O)C(N)=O)CCC1 GIBQQARAXHVEGD-BSOLPCOYSA-N 0.000 abstract 1
- 229950000471 rapastinel Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562242633P | 2015-10-16 | 2015-10-16 | |
| PCT/US2016/057071 WO2017066590A1 (en) | 2015-10-16 | 2016-10-14 | Pharmaceutical combination of an atypical antipsychotic and an nmda modulator for the treatment of schizophrenia,bipolar disorder, cognitive impairment and major depressive disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018004553A true MX2018004553A (es) | 2019-04-15 |
Family
ID=57178579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018004553A MX2018004553A (es) | 2015-10-16 | 2016-10-14 | Combinación farmacéutica de un antipsicótico atípico y un modulador de nmda para el tratamiento de esquizofrenia, trastorno bipolar, deterioro cognitivo y trastorno depresivo mayor. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20180325893A1 (enExample) |
| EP (1) | EP3362080A1 (enExample) |
| JP (2) | JP2018530593A (enExample) |
| KR (1) | KR20180102052A (enExample) |
| CN (1) | CN108601814A (enExample) |
| AU (2) | AU2016340080A1 (enExample) |
| BR (1) | BR112018007681A2 (enExample) |
| CA (1) | CA3002070A1 (enExample) |
| MX (1) | MX2018004553A (enExample) |
| WO (1) | WO2017066590A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017100599A1 (en) | 2015-12-09 | 2017-06-15 | Luc Therapeutics | Thienopyrimidinone nmda receptor modulators and uses thereof |
| ES2821010T3 (es) | 2015-12-09 | 2021-04-23 | Cadent Therapeutics Inc | Moduladores heteroaromáticos del receptor NMDA y usos de los mismos |
| AU2017382339B2 (en) | 2016-12-22 | 2024-02-15 | Novartis Ag | NMDA receptor modulators and uses thereof |
| US20200199173A1 (en) * | 2017-07-28 | 2020-06-25 | Naurex, Inc. | Process and intermediates for synthesis of peptide compounds |
| BR112020009310A2 (pt) | 2017-11-14 | 2020-10-13 | Sk Biopharmaceuticals Co., Ltd. | combinação e composição farmacêutica para a prevenção, alívio ou tratamento da esquizofrenia. |
| DK3505157T3 (da) | 2017-12-29 | 2022-02-28 | Celon Pharma Sa | Tørpulver-ketaminsammensætning til pulmonal indgivelse ved behandlingsresistent depression |
| PT3830092T (pt) | 2018-08-03 | 2023-07-25 | Novartis Ag | Moduladores do recetor nmda heteroaromáticos e suas utilizações |
| US20220024976A1 (en) * | 2019-01-11 | 2022-01-27 | Naurex Inc. | Salt and crystalline forms of rapastinel |
| KR20210060843A (ko) | 2019-11-19 | 2021-05-27 | 뉴트라팜주식회사 | 기억력 및 인지기능 개선, 조현병 예방, 치료 또는 개선용 조성물 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5902815A (en) * | 1996-09-03 | 1999-05-11 | Washington University | Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction |
| KR20040105740A (ko) * | 2002-02-25 | 2004-12-16 | 엘란 파마슈티칼스, 인크. | 염증 치료제의 투여 방법 |
| WO2006066121A2 (en) * | 2004-12-16 | 2006-06-22 | Janssen Pharmaceutica N.V. | Combination of a glycine transporter (glyt1) inhibitor and an antipsychotic for the treatment of symptoms of schizophrenia as well as its preparation and use thereof |
| JP5838021B2 (ja) * | 2005-04-15 | 2015-12-24 | マクロジェニクス，インコーポレーテッド | 共有結合型ダイアボディとその使用 |
| EP2485751B1 (en) * | 2009-10-05 | 2014-05-21 | Northwestern University | GLYX-13 for use in a method of treating refractory depression |
| KR101692275B1 (ko) * | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| SG10201501050RA (en) * | 2010-02-11 | 2015-04-29 | Univ Northwestern | Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof |
| US9737531B2 (en) * | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| MX357761B (es) * | 2011-04-27 | 2018-07-23 | Univ Northwestern | Métodos para tratar la enfermedad de alzheimer, enfermedad de huntington, autismo u otros trastornos. |
| WO2013080046A1 (en) * | 2011-12-02 | 2013-06-06 | Dainippon Sumitomo Pharma Co., Ltd. | Lurasidone novel dosage regimens and use thereof for the treatment, prevention, and/or management of at least one cns disorder |
| EP2906722A4 (en) * | 2012-10-12 | 2016-07-20 | Univ Northwestern | METHOD FOR IDENTIFYING COMPOUNDS FOR THE TREATMENT OF DEPRESSIONS AND RELATED DISEASES |
| US20160345855A1 (en) * | 2013-12-13 | 2016-12-01 | Northwestern University | Methods of treating brain disorders or identifying biomarkers related thereto |
| BR112016025910A8 (pt) * | 2014-05-06 | 2021-07-13 | Univ Northwestern | uso de uma quantidade eficaz de glyx-13, uso de glyx-13 e um antagonista de nmdar e composição farmaceuticamente aceitável compreendendo os mesmos |
| KR20170040351A (ko) * | 2014-08-14 | 2017-04-12 | 노렉스, 인크. | Nmda 조절인자를 사용하여 우울증을 치료하는 방법 |
-
2016
- 2016-10-14 KR KR1020187013668A patent/KR20180102052A/ko not_active Ceased
- 2016-10-14 US US15/773,084 patent/US20180325893A1/en not_active Abandoned
- 2016-10-14 CA CA3002070A patent/CA3002070A1/en not_active Abandoned
- 2016-10-14 WO PCT/US2016/057071 patent/WO2017066590A1/en not_active Ceased
- 2016-10-14 EP EP16784754.0A patent/EP3362080A1/en not_active Withdrawn
- 2016-10-14 JP JP2018519482A patent/JP2018530593A/ja active Pending
- 2016-10-14 BR BR112018007681-3A patent/BR112018007681A2/en not_active IP Right Cessation
- 2016-10-14 CN CN201680064997.4A patent/CN108601814A/zh active Pending
- 2016-10-14 AU AU2016340080A patent/AU2016340080A1/en not_active Abandoned
- 2016-10-14 MX MX2018004553A patent/MX2018004553A/es unknown
-
2022
- 2022-07-04 JP JP2022107539A patent/JP2022140441A/ja active Pending
-
2023
- 2023-08-17 AU AU2023216827A patent/AU2023216827A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2018116882A3 (enExample) | 2020-02-18 |
| US20180325893A1 (en) | 2018-11-15 |
| EP3362080A1 (en) | 2018-08-22 |
| CA3002070A1 (en) | 2017-04-20 |
| JP2022140441A (ja) | 2022-09-26 |
| BR112018007681A2 (en) | 2018-11-06 |
| KR20180102052A (ko) | 2018-09-14 |
| CN108601814A (zh) | 2018-09-28 |
| AU2016340080A1 (en) | 2018-05-10 |
| AU2023216827A1 (en) | 2023-09-07 |
| JP2018530593A (ja) | 2018-10-18 |
| WO2017066590A1 (en) | 2017-04-20 |
| RU2018116882A (ru) | 2019-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP19075354A (es) | Moduladores de k-ras | |
| MA43343A (fr) | Méthodes de conditionnement de patients pour la thérapie cellulaire t | |
| PH12019501079A1 (en) | Magl inhibitors | |
| MX2017011997A (es) | Carbamatos de piperacina y metodos de preparacion y uso. | |
| GB2541571A (en) | Pharmaceutical compositions | |
| PH12017500494A1 (en) | Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof | |
| MX2020011772A (es) | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. | |
| MX2019010949A (es) | Moduladores de somatostatina y usos de los mismos. | |
| MX2019000619A (es) | Compuestos y metodos para la modulacion de smn2. | |
| MX2020002254A (es) | Compuestos espirociclicos y sus metodos de preparacion y uso. | |
| MX2017013785A (es) | Imidazopirazinonas como inhibidores de pde1. | |
| MA40535A (fr) | Imagerie et thérapie d'une inflammation et d'une infection ciblant hsp90 | |
| MX382778B (es) | Metodos para tratar cancer pancreatico | |
| PH12018502154A1 (en) | Methods of treating ocular conditions | |
| ZA201703467B (en) | Methods of treating ocular conditions | |
| HUE063625T2 (hu) | Kezelési rendek és eljárások szklerózis multiplex ofatumumab alkalmazásával történõ kezelésére | |
| PH12018502318A1 (en) | Compositions and methods for treatment of inflammation of infection of the eye | |
| NZ734750A (en) | Cancer therapy with a parvovirus combined with bevacizumab | |
| MX379440B (es) | Moduladores de canales de ca2+ activados de liberación de ca2+ (crac) y usos farmacéuticos de los mismos. | |
| SG11201909851SA (en) | Peptide for inducing regeneration of tissue, and use thereof | |
| PH12017500275A1 (en) | Methods of treating depression using nmda modulators | |
| EP3220845A4 (en) | Medical device for treatment of defective blood vessels, body cavities, and body ducts | |
| PH12018501315A1 (en) | Drug comprising aripiprazole and cilostazol | |
| SG10201903630UA (en) | Iminosugars useful for the treatment of viral diseases | |
| EA201692164A1 (ru) | Лекарственное средство для лечения пациентов с тиннитусом |